未找到相关数据
Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.
被引：2
作者：
Qin, Shukui
Guo, Weijian
Xu, Jian-Ming
Li, Qi
Cheng, Ying
Liu, Tian Shu
Chen, Jiongjie
Chen, Wen-Feng
Li, Jin
机构：
[1] Nanjing Bayi Hosp, Nanjing, Peoples R China
[2] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] 307 Hosp Peoples Liberat Army, Dept Gastrointestinal Oncol, Beijing, Peoples R China
[4] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Shanghai, Peoples R China
[5] Jilin Canc Hosp, Jilin, Jilin, Peoples R China
[6] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[7] Merck Serono Pharmaceut R&D Co Ltd, Beijing, Peoples R China
[8] Tongji Univ, Shanghai East Hosp, Shanghai, Peoples R China
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3521
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3521
引用
收藏
页数：2
相关论文